What is Amgen's UPLIZNA — total revenues?

Amgen (AMGN) reported UPLIZNA — total revenues of $335M in Q2 2026.

What does UPLIZNA — total revenues mean?

This metric captures the total gross sales generated from the commercialization of the specific therapeutic product within the reporting period. It serves as a primary indicator of the product's market adoption, clinical demand, and competitive positioning within its therapeutic class. Tracking this revenue stream allows investors to evaluate the growth trajectory and commercial success of the asset independently of the broader corporate portfolio.

Amgen (AMGN) UPLIZNA — Total revenues

Screener

Other product segments

Repatha

$3.02B—

Other products

$1.7B+23.0%

Prolia

$759M-32.4%

EVENITY

$714M+37.8%

ENBREL

$580M-4.0%

TEPEZZA

$576M+14.1%

Otezla

$491M-20.6%

TEZSPIRE

$486M+42.1%

BLINCYTO

$472M+22.9%

Nplate

$430M+16.5%

KRYSTEXXA

$400M+14.6%

Aranesp

$352M-1.9%

XGEVA

$352M-33.8%

Vectibix

$338M+10.8%

KYPROLIS

$314M-16.9%

IMDELLTRA/IMDYLLTRA

$288M+115%

Similar metrics at other companies

SNDAResident revenue — Total revenues

$108.43M+36.8%

ASSTOther revenue — Total revenues

$43K+514%

ALN

ALNYRoyalty revenue — Total revenues

$71.67M+79.3%

HContra revenue — Total revenues

-$17M-13.3%

FTAIMaintenance revenue — Total revenues

$30.6M-38.3%

FTAIOther revenue — Total revenues

$6.21M+19,923%

Other financials

Income statement

See full

Revenue$10.1B+9.5%

Gross profit$7.2B+17.4%

Operating income$3.5B+32.3%

Net income$2.4B+65.9%

EPS (diluted)$4.37+64.9%

Balance sheet

See full

Cash & equivalents$574.0M+5.9%

Total debt$57.3B+2.0%

Total equity$11.7B+57.4%

Total assets$95.6B+8.8%

Cash flow

See full

Operating cash flow$4.0B+75.5%

CapEx$513.0M+39.0%

Free cash flow$3.5B+82.6%

Valuation

See full

Market cap$220.64B+44.0%

Enterprise value$277.37B+32.8%

P/E25.2×+2.1×

P/S5.8×+1.4×

Profitability

See full

Gross margin69.5%+5.0pp

Operating margin30%+6.5pp

Net margin23%+4.0pp

FCF margin26.7%-3.7pp

Returns & leverage

See full

Return on equity91.5%-7.7pp

Debt / equity4.9×-2.7×

Current ratio1.4×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Amgen’s 10-Q, filed August 5, 2026.

Filed: Aug 4, 2026, 8:00 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000318154-26-000126

Line item	Three months ended June 30, 2026 / U.S.	Three months ended June 30, 2026 / ROW	Three months ended June 30, 2026 / Total	Three months ended June 30, 2025 / U.S.	Three months ended June 30, 2025 / ROW	Three months ended June 30, 2025 / Total
KRYSTEXXA	399	1	400	349	—	349
KYPROLIS	201	113	314	232	146	378
Vectibix	167	171	338	144	161	305
UPLIZNA	317	18	335	132	44	176
IMDELLTRA/IMDYLLTRA	233	55	288	107	27	134
Other products(2)	1,283	414	1,697	990	390	1,380
Total product sales(3)	$6,990	$2,547	9,537	$6,324	$2,447	8,771
Other revenues			517			408

Item 1. FINANCIAL STATEMENTS

FAQ

What is Amgen's UPLIZNA — total revenues?: Amgen (AMGN) reported UPLIZNA — total revenues of $335M in Q2 2026.
What does UPLIZNA — total revenues mean?: This metric captures the total gross sales generated from the commercialization of the specific therapeutic product within the reporting period. It serves as a primary indicator of the product's market adoption, clinical demand, and competitive positioning within its therapeutic class. Tracking this revenue stream allows investors to evaluate the growth trajectory and commercial success of the asset independently of the broader corporate portfolio.